The effect of early Pseudomonas aeruginosa treatment on lung function in pediatric cystic fibrosis

Pediatr Pulmonol. 2011 Jun;46(6):554-8. doi: 10.1002/ppul.21417. Epub 2011 Feb 18.


Objective: Our aim was to assess the effect of treatment of early infection of P. aeruginosa on pulmonary function in pediatric CF patients.

Methods: This was a retrospective cohort study of P. aeruginosa negative CF patients followed at Sick Kids from 1990 to 2007. Early P. aeruginosa infection was defined as the first respiratory culture for P. aeruginosa; patients were included if 5 years of follow-up pulmonary function data were available. Patients were divided into three groups (group 1: never infected, group 2: infected with subsequent clearance, and group 3: chronic infection or still receiving antipseudomonal antibiotics). Hierarchical linear models were used to estimate the effect of P. aeruginosa infection on spirometry. FEV(1) % predicted was the primary outcome.

Results: 116 patients were included. Forty-six (40%) patients remained P. aeruginosa negative throughout the observation period, 29 (25%) patients transiently infected with P. aeruginosa, and 41 (35%) patients were either currently infected or still receiving treatment. Baseline lung function was the same for all groups. Annual decline in FEV(1) % predicted during the study period was not different (-0.6%/year for patients that were never infected and -1.3%/year among patients previously infected).

Conclusions: Lung function was not different between patients with early P. aeruginosa infection and those that never had P. aeruginosa infection. However given the slow rate of FEV(1) decline in the study population, a longer observation period and/or more sensitive outcomes measures may be required to exclude long-term detrimental effects of transient P. aeruginosa infection on lung function in CF patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Child
  • Cohort Studies
  • Cystic Fibrosis / microbiology
  • Cystic Fibrosis / physiopathology*
  • Female
  • Forced Expiratory Volume / physiology*
  • Humans
  • Lung / physiopathology*
  • Male
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas Infections / microbiology
  • Pseudomonas Infections / physiopathology
  • Pseudomonas aeruginosa
  • Respiratory Tract Infections / drug therapy*
  • Respiratory Tract Infections / microbiology
  • Respiratory Tract Infections / physiopathology
  • Retrospective Studies
  • Spirometry
  • Vital Capacity / physiology


  • Anti-Bacterial Agents